Sarepta Therapeutics (SRPT +5.5%) racks up solid gains today after the therapeutic drug...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT +5.5%) racks up solid gains today after the therapeutic drug developer announced positive updated data from its Phase IIb study of eteplirsen in patients with Duchenne muscular dystrophy. Results at 74 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients on a 6-minute walk test.